A Phase 3 interventional study of Ebselen and Placebo in Meniere Disease and Ménière, sponsored by Sound Pharmaceuticals, Incorporated. Completed at 12 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-23.
Sponsored by Sound Pharmaceuticals, Incorporated · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies in Meniere Disease with a site in United States — 3 open to participants now, 7 under way, 1 of them phase 3. Meniere Disease · United States.
Among the 29 studies in Meniere Disease with a site in United States, this one has the largest enrollment of the 28 interventional ones that give a count, is one of 2 that started in 2022, is one of 7 in phase 3, and was the 21st registered.
74 studies on the registry are indexed under Meniere Disease; 12 are open to participants now.
Browse Meniere Disease studies →3 of the 29 studies in Meniere Disease with a site in United States are open now. Recruiting first, the newest first:
University of California, Irvine · Sites in United States
Ages 25–85
National Institute on Deafness and Other Communication Disorders (NIDCD) · Sites in United States
Ages 18–80 · Healthy volunteers
Andrea Vambutas · Sites in United States
Ages 18–75
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 11 Meniere Disease studies recruiting now, 5 (45%) set no upper age limit and 2 (18%) stop at 75 or younger; none take children under 18; 4 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 9 · Phase 3 8 · Phase 4 2
First in 2010; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 220 is above the median of 44 across 61 interventional studies indexed under Meniere Disease.
Median enrollment 40 across the 28 interventional studies, 210 across the 1 observational. Of the 20 that completed or were terminated, 14 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 29 have an industry lead sponsor. The 10 most frequent:
Sound Pharmaceuticals, Incorporated is the lead sponsor of 13 studies on the registry; 2 are open to participants now.
Sound Pharmaceuticals, Incorporated has 5 studies filed under Meniere Disease — fewer than ten, so there is no comparison to draw.
2 of the studies in Meniere Disease with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06859788Phase 3Sound Pharmaceuticals, IncorporatedSPI-1005 for the Treatment of Meniere's Disease (Open Label) | 2026-12 |
| NCT03795675Ohio State UniversityCI Following VS Removal or Labyrinthectomy | 2027-01-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 29 studies in Meniere Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study is a randomized, double-blind, placebo-controlled, multi-center clinical trial (RCT) with open-label extension study (OLE), of SPI-1005 in adult subjects with definite Meniere's disease with active symptoms within three months preceding study enrollment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Oral administration of SPI-1005 400 mg BID for 28 days, with 84-day followup
Drug: Ebselen
Oral administration of matching placebo BID for 28 days, with 84-day followup
Drug: Placebo
Glutathione peroxidase mimetic
Also known as: SPI-1005
Matching placebo containing excipients
Number of Participants With Treatment-Emergent Adverse Events
Number of Participants with Treatment-Emergent Adverse Events (TEAEs)
Time frame: 84 days
Change in Low Frequency Hearing Thresholds Measured by Pure Tone Audiometry
Co-primary efficacy endpoint; assessment of hearing by pure tone audiometry
Time frame: 84 days
Change in Words-in-Noise Test Score
Co-primary efficacy endpoint; assessment of speech discrimination by Words-in-Noise (WIN) Test (WIN Score Improvement from Baseline \>=4 words) The Words-in-Noise (WIN) test is a speech discrimination test which involves the presentation of specific words against a background noise (multi-talker babble). A total of 35 words are presented to each ear, with 5 words presented at each of 7 different signal-to-noise ratios representing increasing difficulty as the test progresses. The WIN Score is the sum total number of words correct (minimum 0, maximum 35) for each ear. A higher WIN Score is considered to be a better outcome. A WIN Score Improvement is an increase in score from baseline. The co-primary efficacy endpoint is the number of participants who had a WIN Score Improvement from Baseline of \>=4 words out of the maximum of 35 words, in one or both ears.
Time frame: 84 days
Change in Tinnitus Severity
Tinnitus Functional Index (0-100) where higher score is worse outcome. Mean change from baseline is reported, where a decrease in score is a better outcome.
Time frame: 84 days
Change in Tinnitus Loudness
Tinnitus Functional Index Question #2 -- How Strong or Loud was your Tinnitus? (0-10) where higher score is worse outcome. Mean change from baseline is reported, where a decrease in score is a better outcome.
Time frame: 84 days
Change in Vertigo Severity
Vertigo Symptom Scale (0-60) where higher score is worse outcome. Mean change from baseline is reported, where a decrease in score is a better outcome.
Time frame: 84 days
Change in Aural Fullness
Aural Fullness Scale (0-10) where higher score is worse outcome. Mean change from baseline is reported, where a decrease in score is a better outcome.
Time frame: 84 days
Change in Dizziness
Dizziness Handicap Inventory (0-100) where higher score is worse outcome. Mean change from baseline is reported, where a decrease in score is a better outcome.
Time frame: 84 days
| Milestone | SPI-1005 400 mg BID | Placebo |
|---|---|---|
| Started | 112 | 108 |
| Completed | 106 | 105 |
| Not completed | 6 | 3 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 |
| Withdrew: Protocol violation | 4 | 3 |
| Milestone | SPI-1005 400 mg BID | Placebo |
|---|---|---|
| Started | 197 | 0 |
| Day 180 (6-months treatment) | 153 | 0 |
| Day 360 (12-months treatment) | 89 | 0 |
| Completed | 125 | 0 |
| Not completed | 72 | 0 |
| Withdrew: Withdrawal by subject | 36 | 0 |
| Withdrew: Protocol violation | 26 | 0 |
| Withdrew: Lost to follow-up | 6 | 0 |
| Withdrew: Physician decision | 2 | 0 |
| Withdrew: Adverse event | 2 | 0 |
Number of Participants with Treatment-Emergent Adverse Events (TEAEs)
| Participants | SPI-1005 400 mg BID | Placebo |
|---|---|---|
| Total Number of Patients with Treatment Emergent Adverse Events (TEAE) | 59 | 45 |
| Number of Patients with Mild TEAE | 32 | 17 |
| Number of Patients with Moderate TEAE | 23 | 26 |
| Number of Patients with Severe TEAE | 4 | 2 |
Co-primary efficacy endpoint; assessment of hearing by pure tone audiometry
| Participants | SPI-1005 400 mg BID | Placebo |
|---|---|---|
| Threshold Improvement from Baseline >=10 dB in at least 1 low frequency (250, 500, or 1000Hz) | 59 | 40 |
| Threshold Improvement from Baseline >=10 dB in 2 adjacent low frequencies (250, 500, or 1000Hz) | 43 | 16 |
Co-primary efficacy endpoint; assessment of speech discrimination by Words-in-Noise (WIN) Test (WIN Score Improvement from Baseline \>=4 words) The Words-in-Noise (WIN) test is a speech discrimination test which involves the presentation of specific words against a background noise (multi-talker babble). A total of 35 words are presented to each ear, with 5 words presented at each of 7 different signal-to-noise ratios representing increasing difficulty as the test progresses. The WIN Score is the sum total number of words correct (minimum 0, maximum 35) for each ear. A higher WIN Score is considered to be a better outcome. A WIN Score Improvement is an increase in score from baseline. The co-primary efficacy endpoint is the number of participants who had a WIN Score Improvement from Baseline of \>=4 words out of the maximum of 35 words, in one or both ears.
| Participants | SPI-1005 400 mg BID | Placebo |
|---|---|---|
| Change in Words-in-Noise Test Score | 45 | 30 |
Tinnitus Functional Index (0-100) where higher score is worse outcome. Mean change from baseline is reported, where a decrease in score is a better outcome.
| scores on a scale | SPI-1005 400 mg BID | Placebo |
|---|---|---|
| Change in Tinnitus Severity | -7.9 ± 20.42 | -6.6 ± 16.15 |
Tinnitus Functional Index Question #2 -- How Strong or Loud was your Tinnitus? (0-10) where higher score is worse outcome. Mean change from baseline is reported, where a decrease in score is a better outcome.
| scores on a scale | SPI-1005 400 mg BID | Placebo |
|---|---|---|
| Change in Tinnitus Loudness | -0.8 ± 2.22 | -0.9 ± 2.16 |
Vertigo Symptom Scale (0-60) where higher score is worse outcome. Mean change from baseline is reported, where a decrease in score is a better outcome.
| scores on a scale | SPI-1005 400 mg BID | Placebo |
|---|---|---|
| Change in Vertigo Severity | -0.3 ± 1.16 | -0.1 ± 1.43 |
Aural Fullness Scale (0-10) where higher score is worse outcome. Mean change from baseline is reported, where a decrease in score is a better outcome.
| scores on a scale | SPI-1005 400 mg BID | Placebo |
|---|---|---|
| Change in Aural Fullness | -1.2 ± 3.00 | -0.6 ± 2.65 |
Dizziness Handicap Inventory (0-100) where higher score is worse outcome. Mean change from baseline is reported, where a decrease in score is a better outcome.
| scores on a scale | SPI-1005 400 mg BID | Placebo |
|---|---|---|
| Change in Dizziness | -5.9 ± 14.71 | -6.1 ± 14.88 |
Collected over SPI-1005 400 mg BID & Placebo: 3 months Open Label Extension: SPI-1005 400 mg BID: 6 to 12 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SPI-1005 400 mg BID | 0/112 (0%) | 2/112 (1.8%) | 25/112 (22.3%) |
| Placebo | 0/108 (0%) | 0/108 (0%) | 19/108 (17.6%) |
| Open Label Extension: SPI-1005 400 mg BID | 0/197 (0%) | 4/197 (2%) | 90/197 (45.7%) |
| Event | SPI-1005 400 mg BID | Placebo | Open Label Extension: SPI-1005 400 mg BID |
|---|---|---|---|
| HypoacusisEar and labyrinth disorders | 1/112 | 0/108 | 0/197 |
| DiverticulitisInfections and infestations | 1/112 | 0/108 | 0/197 |
| NauseaGastrointestinal disorders | 0/112 | 0/108 | 1/197 |
| VomitingGastrointestinal disorders | 0/112 | 0/108 | 1/197 |
| Ankle fractureInjury, poisoning and procedural complications | 0/112 | 0/108 | 1/197 |
| DepressionPsychiatric disorders | 0/112 | 0/108 | 1/197 |
| Knee arthroplastySurgical and medical procedures | 0/112 | 0/108 | 1/197 |
| Event | SPI-1005 400 mg BID | Placebo | Open Label Extension: SPI-1005 400 mg BID |
|---|---|---|---|
| Alanine aminotransferase increasedInvestigations | 1/112 | 11/108 | 32/197 |
| VertigoEar and labyrinth disorders | 11/112 | 9/108 | 25/197 |
| TinnitusEar and labyrinth disorders | 10/112 | 7/108 | 23/197 |
| Aspartate aminotransferase increasedInvestigations | 1/112 | 6/108 | 21/197 |
| COVID-19Infections and infestations | 3/112 | 3/108 | 18/197 |
| HypoacusisEar and labyrinth disorders | 4/112 | 6/108 | 14/197 |
| DizzinessNervous system disorders | 4/112 | 0/108 | 13/197 |
| Ear discomfortEar and labyrinth disorders | 4/112 | 2/108 | 10/197 |
| Age, Continuous(years) | SPI-1005 400 mg BID | Placebo | Total |
|---|---|---|---|
| Mean | 54.5 ± 11.55 | 56.8 ± 10.58 | 55.7 ± 11.12 |
| Sex: Female, Male(Participants) | SPI-1005 400 mg BID | Placebo | Total |
|---|---|---|---|
| Female | 46 | 55 | 101 |
| Male | 66 | 53 | 119 |
| Ethnicity (NIH/OMB)(Participants) | SPI-1005 400 mg BID | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 4 | 5 | 9 |
| Not Hispanic or Latino | 108 | 103 | 211 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | SPI-1005 400 mg BID | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 6 | 1 | 7 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| Black or African American | 6 | 2 | 8 |
| White | 97 | 102 | 199 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 3 | 2 | 5 |
| Region of Enrollment(participants) | SPI-1005 400 mg BID | Placebo | Total |
|---|---|---|---|
| United States | 112 | 108 | 220 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2022 to primary completion in Sep 2023, 13 months.
Results were first posted in Jun 2026, 2 years 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ebselen
Sound Pharmaceuticals, Incorporated